481
Participants
Start Date
June 30, 2003
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
Rituximab
375 mg/m² D-2/D1
Etoposide
100 mg/m² D1-D2-D3
Carboplatine
max 800mg D2
Ifosfamide + Mesna
5 g/m² from D2 to D13
Cisplatine
100 mg/m² from D1 to D13
Cytosine Arabinoside
2000 mg/m²/12 h D2 D3
Dexamethasone
40 mg From D1 to D4
Autologous Stem Cell Transplantation
BCNU
300mg/m² on D-6
Etoposide
200 mg/m² from D-6 to D-3
Cytarabine
100 mg/m² from D-6 to D-3
Melphalan
140 mg/m² on D-2
Memorial Sloan Kettering Cancer Center, New York
Australian leukemia and lymphoma group, Sydney
Groupe d'atude des lymphome de l'adulte, Yvoir
Czech Lymphoma study group, Prague
Hospital district of south west Finland, Turku
German high grade non hodgkin's lymphoma group, Hamburg
Israel Society of Hematology, Tel Litwinsky
Nordic center, Uppsala
Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne
National cancer research institute, London
Lymphoma Study Association
OTHER